A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine

A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine

The coronavirus disease 2019 (COVID-19) mRNA vaccine developed by Pfizer/BioNTech has been shown to be capable of developing an excellent antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, with good production of neutralizing antibodies. Herein,...

Full description

Bibliographic Details
Main Authors: Immacolata Polvere, Serena Voccola, Alfredina Parrella, Gaetano Cardinale, Lucrezia Zerillo, Romualdo Varricchio, Jessica Raffaella Madera, Romania Stilo, Pasquale Vito, Tiziana Zotti
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Vaccines
Subjects:
COVID-19
vaccine
antibodies
ELISA
peptides
Online Access:https://www.mdpi.com/2076-393X/9/9/987

Internet

https://www.mdpi.com/2076-393X/9/9/987

Similar Items